chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: M
Vaccine: COVID19
Symptoms: Anosmia, SARS-CoV-2 test
Clinical narrative: I can't smell but I can taste; This spontaneous case was reported by a consumer and describes the occurrence of ANOSMIA (I can't smell but I can taste) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L207) for COVID-19 vaccination.     The patient's past medical history included Hypertension and Seasonal allergy.    On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jan-2021, the patient experienced ANOSMIA (I can't smell but I can taste). At the time of the report, ANOSMIA (I can't smell but I can taste) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 05-Jan-2021, SARS-CoV-2 test: Negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported No treatment medications were reported.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Pyrexia
Clinical narrative: fever; chills; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever) and CHILLS (chills) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PYREXIA (fever) and CHILLS (chills). At the time of the report, PYREXIA (fever) and CHILLS (chills) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Aphasia
Clinical narrative: Trouble speaking (Aphasia) for 1 minute; This spontaneous case was reported by a consumer and describes the occurrence of APHASIA (Trouble speaking (Aphasia) for 1 minute) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L208) for COVID-19 vaccination.     The patient's past medical history included Brain tumor (brain tumor-1972 removed.)  Concomitant products included ENOXOLONE, GLYCOL SALICYLATE, LEVOMENTHOL, TOCOPHERYL ACETATE (SALONPAS 30).    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Jan-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced APHASIA (Trouble speaking (Aphasia) for 1 minute). On 16-Jan-2021, APHASIA (Trouble speaking (Aphasia) for 1 minute) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medications were not provided.   Reporter did not allow further contact; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.  However, very limited information have been provided about the history of the brain tumor and it could be a confounder for this event.
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: Tested positive for COVID; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (Tested positive for COVID) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SARS-COV-2 TEST POSITIVE (Tested positive for COVID). At the time of the report, SARS-COV-2 TEST POSITIVE (Tested positive for COVID) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No relevant concomitant medications were reported. No treatment information was reported.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Skin discolouration, Vaccination site erythema, Vaccination site pain
Clinical narrative: pink discoloration and bullseye; redness; injection site pain; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of SKIN DISCOLOURATION (pink discoloration and bullseye), VACCINATION SITE ERYTHEMA (redness) and VACCINATION SITE PAIN (injection site pain) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Thyroid cancer (Right lobe removed 1996) in 1996. Concurrent medical conditions included Penicillin allergy, Drug allergy (to Urecholine), Drug allergy (to sulfa), Drug allergy (to cephalosporin), Iodine allergy, Shellfish allergy, Food allergy (to strawberry) and Food allergy (to Banana). Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID) for an unknown indication.    On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Jan-2021, the patient experienced SKIN DISCOLOURATION (pink discoloration and bullseye), VACCINATION SITE ERYTHEMA (redness) and VACCINATION SITE PAIN (injection site pain). At the time of the report, SKIN DISCOLOURATION (pink discoloration and bullseye), VACCINATION SITE ERYTHEMA (redness) and VACCINATION SITE PAIN (injection site pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       for treatment doxycycline was prescribed but not administered. prednisone 40mg dose pack was prescribed, diphenhydramine was used and famotidine was recommended but not administered.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Blood pressure decreased, Dizziness, Heart rate increased, Tachycardia
Clinical narrative: heart rate increased; Abdominal cramp; Dizziness; decrease blood pressure; tachycardia; This spontaneous case was reported by a consumer and describes the occurrence of HEART RATE INCREASED (heart rate increased), ABDOMINAL PAIN (Abdominal cramp), DIZZINESS (Dizziness), BLOOD PRESSURE DECREASED (decrease blood pressure) and TACHYCARDIA (tachycardia) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     Concurrent medical conditions included Shellfish allergy (shellfish and scallops).    On 27-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced HEART RATE INCREASED (heart rate increased), ABDOMINAL PAIN (Abdominal cramp), DIZZINESS (Dizziness), BLOOD PRESSURE DECREASED (decrease blood pressure) and TACHYCARDIA (tachycardia). At the time of the report, HEART RATE INCREASED (heart rate increased), ABDOMINAL PAIN (Abdominal cramp), DIZZINESS (Dizziness), BLOOD PRESSURE DECREASED (decrease blood pressure) and TACHYCARDIA (tachycardia) outcome was unknown.            No relevant concomitant medications were reported. Patient was given diphenhydramine 50 mg in the emergency room for treatment. She reported having no symptoms with first dose.
Age: 90.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Nasopharyngitis, Rhinorrhoea, Vaccination site pain
Clinical narrative: Cough; Runny nose; Got a cold; Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Cough), RHINORRHOEA (Runny nose), NASOPHARYNGITIS (Got a cold) and VACCINATION SITE PAIN (Sore arm) in a 90-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K201A) for COVID-19 vaccination.     Concomitant products included TRAMADOL, TADALAFIL (CIALIS), TAMSULOSIN HYDROCHLORIDE (FLOMAX [TAMSULOSIN HYDROCHLORIDE]), PANTOPRAZOLE, METOPROLOL and ASPIRIN [ACETYLSALICYLIC ACID] for an unknown indication.    On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jan-2021, the patient experienced VACCINATION SITE PAIN (Sore arm). On 19-Jan-2021, the patient experienced COUGH (Cough), RHINORRHOEA (Runny nose) and NASOPHARYNGITIS (Got a cold). On 19-Jan-2021, RHINORRHOEA (Runny nose) and NASOPHARYNGITIS (Got a cold) had resolved. At the time of the report, COUGH (Cough) and VACCINATION SITE PAIN (Sore arm) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medications included 1 cough drop and oxymetazoline hydrochloride nasal swab for runny nose.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site mass, Vaccination site swelling
Clinical narrative: bump came back a week after; Injection site was swollen; injection site bump; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE MASS (injection site bump), VACCINATION SITE MASS (bump came back a week after) and VACCINATION SITE SWELLING (Injection site was swollen) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Jan-2021, the patient experienced VACCINATION SITE MASS (injection site bump) and VACCINATION SITE SWELLING (Injection site was swollen). On 16-Jan-2021, the patient experienced VACCINATION SITE MASS (bump came back a week after). On 11-Jan-2021, VACCINATION SITE MASS (injection site bump) had resolved with sequelae, VACCINATION SITE SWELLING (Injection site was swollen) had resolved. At the time of the report, VACCINATION SITE MASS (bump came back a week after) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. No treatment medications were reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pyrexia, Vaccination site erythema, Vaccination site mass, Vaccination site pain
Clinical narrative: There was a nickel-sized red bump on arm next day that grew and grew; it was warm to touch yesterday; There was a nickel-sized red bump on arm next day that grew and grew; I had an elevated temp; injection site was itchy and red; it started to hurt at night when I'd roll over; injection site was itchy and red; headache; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE MASS (There was a nickel-sized red bump on arm next day that grew and grew), VACCINATION SITE WARMTH (it was warm to touch yesterday), VACCINATION SITE PRURITUS (injection site was itchy and red), VACCINATION SITE SWELLING (There was a nickel-sized red bump on arm next day that grew and grew) and HEADACHE (headache) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 10-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jan-2021, the patient experienced HEADACHE (headache). On 16-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (injection site was itchy and red), VACCINATION SITE ERYTHEMA (injection site was itchy and red) and VACCINATION SITE PAIN (it started to hurt at night when I'd roll over). On 17-Jan-2021, the patient experienced VACCINATION SITE MASS (There was a nickel-sized red bump on arm next day that grew and grew), VACCINATION SITE WARMTH (it was warm to touch yesterday), VACCINATION SITE SWELLING (There was a nickel-sized red bump on arm next day that grew and grew) and PYREXIA (I had an elevated temp). On 11-Jan-2021, HEADACHE (headache) had resolved. At the time of the report, VACCINATION SITE MASS (There was a nickel-sized red bump on arm next day that grew and grew), VACCINATION SITE WARMTH (it was warm to touch yesterday), VACCINATION SITE PRURITUS (injection site was itchy and red), VACCINATION SITE SWELLING (There was a nickel-sized red bump on arm next day that grew and grew), VACCINATION SITE ERYTHEMA (injection site was itchy and red), VACCINATION SITE PAIN (it started to hurt at night when I'd roll over) and PYREXIA (I had an elevated temp) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.  Patient took ibuprofen to help with symptoms starting 17Jan2021
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pruritus, Vaccination site swelling, Vaccination site warmth
Clinical narrative: There was a nickel-sized red bump on arm next day that grew and grew; it was warm to touch yesterday; There was a nickel-sized red bump on arm next day that grew and grew; I had an elevated temp; injection site was itchy and red; it started to hurt at night when I'd roll over; injection site was itchy and red; headache; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE MASS (There was a nickel-sized red bump on arm next day that grew and grew), VACCINATION SITE WARMTH (it was warm to touch yesterday), VACCINATION SITE PRURITUS (injection site was itchy and red), VACCINATION SITE SWELLING (There was a nickel-sized red bump on arm next day that grew and grew) and HEADACHE (headache) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 10-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jan-2021, the patient experienced HEADACHE (headache). On 16-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (injection site was itchy and red), VACCINATION SITE ERYTHEMA (injection site was itchy and red) and VACCINATION SITE PAIN (it started to hurt at night when I'd roll over). On 17-Jan-2021, the patient experienced VACCINATION SITE MASS (There was a nickel-sized red bump on arm next day that grew and grew), VACCINATION SITE WARMTH (it was warm to touch yesterday), VACCINATION SITE SWELLING (There was a nickel-sized red bump on arm next day that grew and grew) and PYREXIA (I had an elevated temp). On 11-Jan-2021, HEADACHE (headache) had resolved. At the time of the report, VACCINATION SITE MASS (There was a nickel-sized red bump on arm next day that grew and grew), VACCINATION SITE WARMTH (it was warm to touch yesterday), VACCINATION SITE PRURITUS (injection site was itchy and red), VACCINATION SITE SWELLING (There was a nickel-sized red bump on arm next day that grew and grew), VACCINATION SITE ERYTHEMA (injection site was itchy and red), VACCINATION SITE PAIN (it started to hurt at night when I'd roll over) and PYREXIA (I had an elevated temp) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.  Patient took ibuprofen to help with symptoms starting 17Jan2021
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Vaccination site pain, Vaccination site rash, Vaccination site swelling
Clinical narrative: Redness upto armpit; Rash at injection site.; Vaccination site pain.; Swelling at vaccination site; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Redness upto armpit), VACCINATION SITE RASH (Rash at injection site.), VACCINATION SITE PAIN (Vaccination site pain.) and VACCINATION SITE SWELLING (Swelling at vaccination site) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Jan-2021, the patient experienced ERYTHEMA (Redness upto armpit), VACCINATION SITE RASH (Rash at injection site.), VACCINATION SITE PAIN (Vaccination site pain.) and VACCINATION SITE SWELLING (Swelling at vaccination site). At the time of the report, ERYTHEMA (Redness upto armpit), VACCINATION SITE RASH (Rash at injection site.), VACCINATION SITE PAIN (Vaccination site pain.) and VACCINATION SITE SWELLING (Swelling at vaccination site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No treatment medications were reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Anxiety, Diarrhoea, Dizziness, Feeding disorder, Myalgia
Clinical narrative: anxious; dizziness; can't eat anything; nauseous; achiness all over the body; fever; diarrhea, on and off diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (diarrhea, on and off diarrhea), ANXIETY (anxious), DIZZINESS (dizziness), FEEDING DISORDER (can't eat anything) and NAUSEA (nauseous) in a 45-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included VENLAFAXINE HYDROCHLORIDE (EFFEXOR) for Depression.    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced DIARRHOEA (diarrhea, on and off diarrhea), MYALGIA (achiness all over the body) and PYREXIA (fever). On 17-Jan-2021, the patient experienced ANXIETY (anxious), DIZZINESS (dizziness), FEEDING DISORDER (can't eat anything) and NAUSEA (nauseous). On 15-Jan-2021, MYALGIA (achiness all over the body) and PYREXIA (fever) had resolved. At the time of the report, DIARRHOEA (diarrhea, on and off diarrhea), ANXIETY (anxious), DIZZINESS (dizziness), FEEDING DISORDER (can't eat anything) and NAUSEA (nauseous) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       patient took Pepto-Bismol to treat nausea and diarrhea symptoms.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Nausea, Pyrexia
Clinical narrative: anxious; dizziness; can't eat anything; nauseous; achiness all over the body; fever; diarrhea, on and off diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (diarrhea, on and off diarrhea), ANXIETY (anxious), DIZZINESS (dizziness), FEEDING DISORDER (can't eat anything) and NAUSEA (nauseous) in a 45-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included VENLAFAXINE HYDROCHLORIDE (EFFEXOR) for Depression.    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced DIARRHOEA (diarrhea, on and off diarrhea), MYALGIA (achiness all over the body) and PYREXIA (fever). On 17-Jan-2021, the patient experienced ANXIETY (anxious), DIZZINESS (dizziness), FEEDING DISORDER (can't eat anything) and NAUSEA (nauseous). On 15-Jan-2021, MYALGIA (achiness all over the body) and PYREXIA (fever) had resolved. At the time of the report, DIARRHOEA (diarrhea, on and off diarrhea), ANXIETY (anxious), DIZZINESS (dizziness), FEEDING DISORDER (can't eat anything) and NAUSEA (nauseous) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       patient took Pepto-Bismol to treat nausea and diarrhea symptoms.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Pruritus
Clinical narrative: Left arm felt burning; Left arm felt Itchy; This spontaneous case was reported by a consumer and describes the occurrence of BURNING SENSATION (Left arm felt burning) and PRURITUS (Left arm felt Itchy) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy.    On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jan-2021, the patient experienced BURNING SENSATION (Left arm felt burning) and PRURITUS (Left arm felt Itchy). The patient was treated with FLUOCINONIDE from 16-Jan-2021 to 17-Jan-2021 for Burning sensation and Itchy, at a dose of .5 % three times a day. At the time of the report, BURNING SENSATION (Left arm felt burning) and PRURITUS (Left arm felt Itchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 13-Apr-2021: Follow-up received on 13 Apr 2021, patient denied further contact
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Pruritus, Urticaria
Clinical narrative: red, itchy welts; Red raised itchy welts on same arm; Red raised itchy welts on same arm; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (red, itchy welts), ERYTHEMA (Red raised itchy welts on same arm) and PRURITUS (Red raised itchy welts on same arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Jan-2021, the patient experienced URTICARIA (red, itchy welts), ERYTHEMA (Red raised itchy welts on same arm) and PRURITUS (Red raised itchy welts on same arm). At the time of the report, URTICARIA (red, itchy welts), ERYTHEMA (Red raised itchy welts on same arm) and PRURITUS (Red raised itchy welts on same arm) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 18-Jan-2021: Major narrative update
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Vaccination site erythema, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: itchiness at the injection site; swelling at injection site; redness at injection site; muscle soreness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (itchiness at the injection site), VACCINATION SITE SWELLING (swelling at injection site), MYALGIA (muscle soreness) and VACCINATION SITE ERYTHEMA (redness at injection site) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced MYALGIA (muscle soreness). On 16-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (itchiness at the injection site), VACCINATION SITE SWELLING (swelling at injection site) and VACCINATION SITE ERYTHEMA (redness at injection site). At the time of the report, VACCINATION SITE PRURITUS (itchiness at the injection site), VACCINATION SITE SWELLING (swelling at injection site), MYALGIA (muscle soreness) and VACCINATION SITE ERYTHEMA (redness at injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   no relevant concomitant medications were reported. No treatment medications were reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain
Clinical narrative: Lymph nodes are tender; This spontaneous case was reported by a consumer and describes the occurrence of LYMPH NODE PAIN (Lymph nodes are tender) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In January 2021, the patient experienced LYMPH NODE PAIN (Lymph nodes are tender). At the time of the report, LYMPH NODE PAIN (Lymph nodes are tender) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. Treatment medications included unspecified steroids and antibiotics.   Reporter did not allow further contact; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Hypoacusis, Tinnitus
Clinical narrative: having tinnitus, ringing in her ears; It's much worse, harder to hear now; This spontaneous case was reported by a nurse and describes the occurrence of TINNITUS (having tinnitus, ringing in her ears) and HYPOACUSIS (It's much worse, harder to hear now) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Jan-2021, the patient experienced HYPOACUSIS (It's much worse, harder to hear now). On an unknown date, the patient experienced TINNITUS (having tinnitus, ringing in her ears). At the time of the report, TINNITUS (having tinnitus, ringing in her ears) and HYPOACUSIS (It's much worse, harder to hear now) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  No treatment information was provided.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Tenderness
Clinical narrative: arm pain; Arm tenderness that last half day; This spontaneous case was reported by a consumer and describes the occurrence of TENDERNESS (Arm tenderness that last half day) and PAIN IN EXTREMITY (arm pain) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Jan-2021, the patient experienced TENDERNESS (Arm tenderness that last half day). On an unknown date, the patient experienced PAIN IN EXTREMITY (arm pain). At the time of the report, TENDERNESS (Arm tenderness that last half day) and PAIN IN EXTREMITY (arm pain) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The Concomitant medications were not provided. The Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 25-May-2021: Event Onset Date, 1st and 2nd dose date and event updated; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Blood glucose, Hypoglycaemia, Tremor, Vaccination site discolouration, Vaccination site pain
Clinical narrative: Sugar below was 65; injection site was black; she was shaky; injection site was swollen; injection site was painful; This spontaneous case was reported by a consumer and describes the occurrence of HYPOGLYCAEMIA (Sugar below was 65), VACCINATION SITE DISCOLOURATION (injection site was black), TREMOR (she was shaky), VACCINATION SITE SWELLING (injection site was swollen) and VACCINATION SITE PAIN (injection site was painful) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028L20A and 012M20A) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-Jan-2021, the patient experienced HYPOGLYCAEMIA (Sugar below was 65), VACCINATION SITE DISCOLOURATION (injection site was black), TREMOR (she was shaky), VACCINATION SITE SWELLING (injection site was swollen) and VACCINATION SITE PAIN (injection site was painful). On 15-Jan-2021, HYPOGLYCAEMIA (Sugar below was 65) had resolved. At the time of the report, VACCINATION SITE DISCOLOURATION (injection site was black), TREMOR (she was shaky), VACCINATION SITE SWELLING (injection site was swollen) and VACCINATION SITE PAIN (injection site was painful) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Jan-2021, Blood glucose: 65 (Low) Blood glucose decreased and 125 (Inconclusive) Blood glucose elevated to 125 after taking cookies and milk.         Concomitant and Treatment drugs were not provided   Most recent FOLLOW-UP information incorporated above includes: On 13-Apr-2021: Follow-up received on 13-Apr-2021: Updated event outcome and dose 2 of mRNA-1273 vaccine. On 02-Jul-2021: Follow up received on 2-JUL-2021 TCR attached patient denies further follow up consent; Sender's Comments: Based on current available information and the temporal association between product use and the start date of the events a causal relationship cannot be ruled out.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site swelling
Clinical narrative: Sugar below was 65; injection site was black; she was shaky; injection site was swollen; injection site was painful; This spontaneous case was reported by a consumer and describes the occurrence of HYPOGLYCAEMIA (Sugar below was 65), VACCINATION SITE DISCOLOURATION (injection site was black), TREMOR (she was shaky), VACCINATION SITE SWELLING (injection site was swollen) and VACCINATION SITE PAIN (injection site was painful) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028L20A and 012M20A) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-Jan-2021, the patient experienced HYPOGLYCAEMIA (Sugar below was 65), VACCINATION SITE DISCOLOURATION (injection site was black), TREMOR (she was shaky), VACCINATION SITE SWELLING (injection site was swollen) and VACCINATION SITE PAIN (injection site was painful). On 15-Jan-2021, HYPOGLYCAEMIA (Sugar below was 65) had resolved. At the time of the report, VACCINATION SITE DISCOLOURATION (injection site was black), TREMOR (she was shaky), VACCINATION SITE SWELLING (injection site was swollen) and VACCINATION SITE PAIN (injection site was painful) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Jan-2021, Blood glucose: 65 (Low) Blood glucose decreased and 125 (Inconclusive) Blood glucose elevated to 125 after taking cookies and milk.         Concomitant and Treatment drugs were not provided   Most recent FOLLOW-UP information incorporated above includes: On 13-Apr-2021: Follow-up received on 13-Apr-2021: Updated event outcome and dose 2 of mRNA-1273 vaccine. On 02-Jul-2021: Follow up received on 2-JUL-2021 TCR attached patient denies further follow up consent; Sender's Comments: Based on current available information and the temporal association between product use and the start date of the events a causal relationship cannot be ruled out.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Rash erythematous, Tachycardia, Vaccination site erythema, Vaccination site pruritus
Clinical narrative: Tachycardia on and off; whole bodyerythema rash; generalized rash; Injection site itching; Big rash on the injection site; red on the site of injection; Swollen at the injection site; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of TACHYCARDIA (Tachycardia on and off), RASH ERYTHEMATOUS (whole bodyerythema rash), RASH (generalized rash), VACCINATION SITE PRURITUS (Injection site itching) and VACCINATION SITE RASH (Big rash on the injection site) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025S202A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced TACHYCARDIA (Tachycardia on and off), RASH ERYTHEMATOUS (whole bodyerythema rash), RASH (generalized rash), VACCINATION SITE PRURITUS (Injection site itching), VACCINATION SITE RASH (Big rash on the injection site), VACCINATION SITE ERYTHEMA (red on the site of injection) and VACCINATION SITE SWELLING (Swollen at the injection site). The patient was treated with PREDNISONE (oral) for Rash, at a dose of 10 milligram. At the time of the report, TACHYCARDIA (Tachycardia on and off), RASH ERYTHEMATOUS (whole bodyerythema rash), RASH (generalized rash), VACCINATION SITE PRURITUS (Injection site itching), VACCINATION SITE RASH (Big rash on the injection site), VACCINATION SITE ERYTHEMA (red on the site of injection) and VACCINATION SITE SWELLING (Swollen at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Upon in internal review on 19 May 2021, the age was corrected to 75 years. No relevant concomitant medications were reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site rash, Vaccination site swelling
Clinical narrative: Tachycardia on and off; whole bodyerythema rash; generalized rash; Injection site itching; Big rash on the injection site; red on the site of injection; Swollen at the injection site; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of TACHYCARDIA (Tachycardia on and off), RASH ERYTHEMATOUS (whole bodyerythema rash), RASH (generalized rash), VACCINATION SITE PRURITUS (Injection site itching) and VACCINATION SITE RASH (Big rash on the injection site) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025S202A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced TACHYCARDIA (Tachycardia on and off), RASH ERYTHEMATOUS (whole bodyerythema rash), RASH (generalized rash), VACCINATION SITE PRURITUS (Injection site itching), VACCINATION SITE RASH (Big rash on the injection site), VACCINATION SITE ERYTHEMA (red on the site of injection) and VACCINATION SITE SWELLING (Swollen at the injection site). The patient was treated with PREDNISONE (oral) for Rash, at a dose of 10 milligram. At the time of the report, TACHYCARDIA (Tachycardia on and off), RASH ERYTHEMATOUS (whole bodyerythema rash), RASH (generalized rash), VACCINATION SITE PRURITUS (Injection site itching), VACCINATION SITE RASH (Big rash on the injection site), VACCINATION SITE ERYTHEMA (red on the site of injection) and VACCINATION SITE SWELLING (Swollen at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Upon in internal review on 19 May 2021, the age was corrected to 75 years. No relevant concomitant medications were reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Injection site mass, Pain in extremity, Vaccination site discolouration, Vaccination site discomfort
Clinical narrative: Arm started to hurt; Cheeks got bright red; in her arm she has a lump; Discomfort; Bullseye that is about 3 inches big all around; Redness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm started to hurt), ERYTHEMA (Cheeks got bright red), INJECTION SITE MASS (in her arm she has a lump), VACCINATION SITE DISCOMFORT (Discomfort) and VACCINATION SITE DISCOLOURATION (Bullseye that is about 3 inches big all around) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 09-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jan-2021, the patient experienced PAIN IN EXTREMITY (Arm started to hurt), ERYTHEMA (Cheeks got bright red), INJECTION SITE MASS (in her arm she has a lump), VACCINATION SITE DISCOMFORT (Discomfort), VACCINATION SITE DISCOLOURATION (Bullseye that is about 3 inches big all around) and VACCINATION SITE ERYTHEMA (Redness). On 11-Jan-2021, ERYTHEMA (Cheeks got bright red) had resolved. At the time of the report, PAIN IN EXTREMITY (Arm started to hurt), INJECTION SITE MASS (in her arm she has a lump), VACCINATION SITE DISCOMFORT (Discomfort), VACCINATION SITE DISCOLOURATION (Bullseye that is about 3 inches big all around) and VACCINATION SITE ERYTHEMA (Redness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. Patient reported she put ice and took diphenhydramine for treatment but it did not make significant difference.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema
Clinical narrative: Arm started to hurt; Cheeks got bright red; in her arm she has a lump; Discomfort; Bullseye that is about 3 inches big all around; Redness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm started to hurt), ERYTHEMA (Cheeks got bright red), INJECTION SITE MASS (in her arm she has a lump), VACCINATION SITE DISCOMFORT (Discomfort) and VACCINATION SITE DISCOLOURATION (Bullseye that is about 3 inches big all around) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 09-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jan-2021, the patient experienced PAIN IN EXTREMITY (Arm started to hurt), ERYTHEMA (Cheeks got bright red), INJECTION SITE MASS (in her arm she has a lump), VACCINATION SITE DISCOMFORT (Discomfort), VACCINATION SITE DISCOLOURATION (Bullseye that is about 3 inches big all around) and VACCINATION SITE ERYTHEMA (Redness). On 11-Jan-2021, ERYTHEMA (Cheeks got bright red) had resolved. At the time of the report, PAIN IN EXTREMITY (Arm started to hurt), INJECTION SITE MASS (in her arm she has a lump), VACCINATION SITE DISCOMFORT (Discomfort), VACCINATION SITE DISCOLOURATION (Bullseye that is about 3 inches big all around) and VACCINATION SITE ERYTHEMA (Redness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. Patient reported she put ice and took diphenhydramine for treatment but it did not make significant difference.
Sex: F
Vaccine: COVID19
Symptoms: Urticaria, Vaccination site erythema, Vaccination site pain, Vaccination site pruritus
Clinical narrative: 3-4 hives along hairline; 5cm area of pruritus at injection site; 5cm area of erythema at injection site; pain at the injection site; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of URTICARIA (3-4 hives along hairline), VACCINATION SITE PRURITUS (5cm area of pruritus at injection site), VACCINATION SITE ERYTHEMA (5cm area of erythema at injection site) and VACCINATION SITE PAIN (pain at the injection site) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Hashimoto's thyroiditis. Concurrent medical conditions included Psoriatic arthritis. Concomitant products included STEROID DOSE PAK for Psoriatic arthritis.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced URTICARIA (3-4 hives along hairline), VACCINATION SITE PRURITUS (5cm area of pruritus at injection site), VACCINATION SITE ERYTHEMA (5cm area of erythema at injection site) and VACCINATION SITE PAIN (pain at the injection site). On 18-Jan-2021, VACCINATION SITE PRURITUS (5cm area of pruritus at injection site) was resolving. At the time of the report, URTICARIA (3-4 hives along hairline) had resolved, VACCINATION SITE ERYTHEMA (5cm area of erythema at injection site) was resolving and VACCINATION SITE PAIN (pain at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) and mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Most recent FOLLOW-UP information incorporated above includes: On 16-Jan-2021: Additional info received on 13-Apr-2021.Second dose and causality of event hives was updated.
Age: 82.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Chills, Pyrexia
Clinical narrative: Achy joint pain on both sides; Mild Fever of 100.9; Mild chills but not shaking; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of ARTHRALGIA (Achy joint pain on both sides), PYREXIA (Mild Fever of 100.9) and CHILLS (Mild chills but not shaking) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Jan-2021, the patient experienced ARTHRALGIA (Achy joint pain on both sides), PYREXIA (Mild Fever of 100.9) and CHILLS (Mild chills but not shaking). At the time of the report, ARTHRALGIA (Achy joint pain on both sides), PYREXIA (Mild Fever of 100.9) and CHILLS (Mild chills but not shaking) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 16-Jan-2021, Body temperature: 100.9 High.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.   Patients Physician suggested Tylenol but she did not report taking it as yet.
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: Contracted covid (Positive test); This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Contracted covid (Positive test)) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jan-2021, the patient experienced COVID-19 (Contracted covid (Positive test)). At the time of the report, COVID-19 (Contracted covid (Positive test)) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 09-Jan-2021, SARS-CoV-2 test: (Positive) Contracted covid.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided. treatment medication reported was Tylenol.
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: rash with bumps from arm to whole body, itchy and sometimes hurt; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (rash with bumps from arm to whole body, itchy and sometimes hurt) in an 83-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Jan-2021, the patient experienced URTICARIA (rash with bumps from arm to whole body, itchy and sometimes hurt). At the time of the report, URTICARIA (rash with bumps from arm to whole body, itchy and sometimes hurt) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No treatment medications were reported